On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...

a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases. With the ...

Today, BioNTech revealed a definitive agreement to acquire China-based Biotheus, a clinical-stage biotechnology company ...

Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to ...

Finally, there's Guardant Health, a developer of oncological tests. It also put out fresh financials late last week, and of ...

Researchers at Tel Aviv University (TAU) can add to that list their important discovery of a cancer mechanism that has been ...

GE HealthCare (Nasdaq:GEHC) announced today that it received FDA 510(k) clearance for its Signa Magnus MRI scanner.

CHICAGO--GE HealthCare (Nasdaq: GEHC) has received FDA 510(k) clearance for its innovative SIGNA™ MAGNUS,i a 3.0T ...

The system offers new capabilities for both clinical imaging and neuroscience with the potential to aid in the detection of neurological, oncological, and psychiatric conditions. The company noted ...

SCIEX and a triple partnership with GSK, UCL, and Yokogawa In conversation with pharmaphorum about the oncological possibilities of her research, Bailey posited that her team is perhaps “a ...

Procedures like partial nephrectomy for kidney cancer, endoscopic resection or partial cystectomy for bladder cancer, and ...

Despite reports this fall that the two payers had reopened merger talks, Cigna plans to use excess cash to buy back its ...